Trust is the essence of every brand and, in the pharmaceutical industry, this depends on the ability to deliver products of a consistently high standard. For more than 25 years our focus on quality has earned our ‘own brand’ generics a high reputation and encouraged numerous multinationals to turn to us to manufacture and market their branded pharmaceuticals, under ‘in-licensing’ agreements.

Focused on the MENA region

Most of our branded products are sold in the MENA region, where branded pharmaceuticals - both generics and patented - dominate the market. Our biggest markets are Algeria, Jordan and Saudi Arabia. We also sell branded pharmaceuticals in Europe.

Broad product portfolio

Our branded business sells 241 solid, semi-solid and liquid products in 460 dosage strengths and forms. Our core strengths lie in the anti-infective, immunomodulating agent, musculoskeletal and, increasingly, cardiovascular therapeutic categories. 35 new products are under development.

Powerful marketing capability

Our 1090-strong sales and marketing team is one of the largest in the MENA region, enabling us to build close relationships with key stakeholders and optimise the commercial potential of the products we market.

Large customer base

We have over 2,000 customers in the MENA region. The size of our customer base is not only a testament to the quality of our products and marketing, it also reduces the commercial risks of being overly dependent on a single customer or group of customers.

Local manufacturing

Branded pharmaceuticals are manufactured at our facilities in Jordan - all certified by the FDA and MHRA, as well as at our FDA approved facility in Saudi Arabia and our new plant in Algeria.

Proven experience with in-licensors

We believe that our strong presence in the MENA Region makes us an attractive partner for multinational pharmaceutical companies seeking access to this region. Currently, the Branded business sells 33 under-licensed products. The Branded business also has a further 16 under-licensed products pending launch.